Non-peptide

ABS-201

Also known as

ABS201 · ABS 201 · prolactin receptor antagonist hair · Absci ABS-201

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Compound	An investigational antibody aimed at the prolactin receptor, being studied for pattern hair loss.
Forms studied	Single doses into a vein and repeated injections beneath the skin are separate trial arms.

Notes

ABS-201 is an investigational prolactin-receptor antibody being developed for hair loss.

An antibody aimed at the prolactin receptor. ABS-201 is a large engineered protein designed to block the receptor that receives prolactin signals. This is a different approach from finasteride, minoxidil or PP405. Blocking that receptor is also different from lowering a blood prolactin result. NCT07317544 current protocol registration (Official context · Accessed 2026-09-30) · Prolactin the Cause of Hair Loss? ABS-201 the Cure? (Community opinion · Accessed 2026-09-30)

Injection research, with two distinct routes. The registered study separates single IV doses, delivered into a vein, from repeated SC doses, injected beneath the skin. These are different delivery methods and study arms. A claimed gray-market vial or peptide-style recipe cannot verify the named trial product. NCT07317544 current protocol registration (Official context · Accessed 2026-09-30)

Source context — NCT07317544 current protocol registration: Sponsor-submitted registry, last update posted September 3 2026. Protocol entries describe intended arms, not completed results. Study webpage yielded only shell; API supplied actual body.

Source context — Prolactin the Cause of Hair Loss? ABS-201 the Cure?: User's research interpretation, not personal ABS-201 exposure. Linked literature not all opened. HMI-115, animal and cell-culture observations retain those origins; author predictions are not validated.

What people notice

Hair changes	The inspected accounts do not establish firsthand regrowth. Thicker hair, fewer treatment days and pigment changes are hopes in the discussion.
An ambiguous adverse account	One trial-related commenter mentions constipation and a hemorrhoid, without confirming active drug, dose or placebo status.

Notes

The inspected discussion covers trial announcements and injection convenience. It provides no firsthand hair-regrowth or day-to-day feel report. ABS-201 interim Phase 1 news discussion (Community discussion · Accessed 2026-09-22)

Thicker coverage, not just less shedding. Hair-loss posters hope miniaturized hairs will become visibly thicker again. smurfsays considers the target promising but doubts it will fully reverse baldness. That is a reasoned community prediction, not a result from taking ABS-201. Prolactin the Cause of Hair Loss? ABS-201 the Cure? (Community opinion · Accessed 2026-09-30)

Fewer treatment days and possible pigment changes. Interview replies imagine an alternative to constant medication and discuss gray-hair reversal. The same exchange pushes back on calling it a cure and worries about future cost. Regrowth, pigmentation and sexual-function claims remain expectations, not demonstrated personal benefits. Discussion of interview with Absci founder (Community discussion · Accessed 2026-09-30)

An apparent adverse reply has important missing context. Affectionate-Let4751 later mentions constipation and a hemorrhoid. Their trial-related comments do not identify dose, confirmed ABS-201 receipt, placebo status or causality. This remains one ambiguous account, not two side-effect reports or an established drug reaction. Australian hair-loss trial: eligibility, travel and participant concerns (Community discussion · Accessed 2026-09-30) · Anyone participating in HEADLINE ABS-201? (Community discussion · Accessed 2026-09-30)

Source context — ABS-201 interim Phase 1 news discussion: News repost and opinion, not confirmed participation. Sponsor safety/PK claims are not independently verified here or proof of hair efficacy.

Source context — Discussion of interview with Absci founder: Author says interview not fully watched; video itself not inspected. Predictions about hair counts and sexual function not results. Cost worries are speculation, no actual price. Same CandidMeringue2790 as hmi-dispute.

Source context — Australian hair-loss trial: eligibility, travel and participant concerns: Unverified screening stories and opinions. Shellfish rejection is one repeated account; no general allergy rule inferred. Constipation/hemorrhoid reply lacks dose, allocation and confirmed ABS-201 exposure. Reimbursement and access instructions excluded.

Source context — Anyone participating in HEADLINE ABS-201?: Visible replies discuss visit/time commitments, not confirmed benefit. Deleted comments and collapsed replies not inspected. Same Affectionate-Let4751 as trial-tradeoffs, not an independent adverse account.

Doses people talk about

Community amount	No documented self-use amount with route, frequency and outcome emerges from these accounts.
Single IV trial doses	150, 450, 900 or 1,800 mg per administration are separate study cohorts, not daily consumer amounts.
Repeated under-skin trial doses	300, 600 or 1,200 mg per administration, or placebo. These trial arms cannot be exchanged with the IV amounts.

Notes

No established community dose or daily total. These discussions provide trial announcements and questions, not a documented self-use amount with route, frequency and outcome. No dependable consumer quantity emerges from these accounts. Trial milligrams are kept separately below; they are not a daily injection chart. ABS-201 trial question: surviving replies after OP deletion (Community discussion · Accessed 2026-09-30)

Trial amounts are separate from consumer practice. Absci lists single IV cohorts of 150, 450, 900 and 1,800 mg; repeated SC cohorts use 300, 600 or 1,200 mg per administration, or placebo. These are distinct study arms, not daily totals or interchangeable routes. Absci June 24 interim HEADLINE Phase 1 release (Official context · Accessed 2026-09-30)

Source context — ABS-201 trial question: surviving replies after OP deletion: Original post deleted. Replies ask for enrollment and hair-growth updates but give no response timeline. Tressless summary is only a discovery lead, not a reconstructed OP.

Source context — Absci June 24 interim HEADLINE Phase 1 release: Sponsor press release, blinded aggregate interim data with placebo mixed in; not independent review, finalized half-life or efficacy publication. Shared origin with forum reposts.

Half-life, onset & duration

Felt onset	No dependable firsthand timeline for regrowth or bodily changes is established in the inspected accounts.
Felt duration	Unknown here. Years-long hopes come from earlier anti-prolactin-receptor animal work, not human ABS-201 follow-up.
Half-life	At least 65 days is a provisional sponsor-derived estimate after single IV trial doses; it does not measure hair-benefit duration.

Notes

No dependable firsthand regrowth or feel-clock here. Surviving replies to a deleted trial-question post ask whether enrollment happened and how hair growth is going; they do not supply an answer. A prediction about a future hair-count assessment cannot establish when a participant first sees growth, shedding or a bodily change. ABS-201 trial question: surviving replies after OP deletion (Community discussion · Accessed 2026-09-30)

Years of regrowth are animal-comparator lore. One HMI-115 comparison thread turns four-year macaque follow-up into hope for lasting ABS-201 benefit. Those earlier anti-prolactin-receptor animal observations do not measure human ABS-201 durability. No inspected personal account establishes persistence after stopping. HopeMed HMI-115 versus Absci ABS-201 dispute (Community discussion · Accessed 2026-09-30) · Prolactin the Cause of Hair Loss? ABS-201 the Cure? (Community opinion · Accessed 2026-09-30)

At least 65 days: a sponsor-derived human trial estimate. This number circulates in the Phase 1 news repost. It originates in Absci's interim blood-concentration data after single IV trial doses, not a community measurement. It is a provisional estimate, not a countdown to complete clearance or the length of hair improvement. ABS-201 interim Phase 1 announcement repost (Secondhand community claim · Accessed 2026-09-30)

Source context — HopeMed HMI-115 versus Absci ABS-201 dispute: Reposted company complaint not independently adjudicated. Comments claiming complete safety, tenfold underdosing or inevitable durability are opinion. Four-year durability refers to earlier anti-PRLR macaque material, not ABS-201 humans.

Source context — ABS-201 interim Phase 1 announcement repost: Sponsor news repost, not trial participation or independent measurements. Numeric half-life and injection target originate in Absci's June 24 release. No outcome comments visible.

Cycles people discuss

Injection interval being developed	Two or three injections over six months is a sponsor development target, not a community-tested course.
Repeat treatment	The discussions do not establish a repeat-course calendar, time off or whether maintenance would be needed.

Notes

Two or three injections over six months is a development target. The announcement repost repeats Absci's proposed interval, derived from trial drug-level data. It is not a community-tested cycle. The discussions do not establish a repeat-course calendar, time off or whether maintenance would be needed. ABS-201 interim Phase 1 announcement repost (Secondhand community claim · Accessed 2026-09-30)

Stacks

Combinations	No tested ABS-201 combination is described. HMI-115, PP405, GT20029, pyrilutamide, finasteride and minoxidil are comparison names.

Notes

HMI-115 comparisons are disputed, not a stack. Posts argue about potency, receptor coverage and absent hair-loss data; a HopeMed complaint is also reposted. The dispute does not prove either drug's superiority. PP405, GT20029, pyrilutamide, finasteride and minoxidil remain comparison names, not a tested ABS-201 combination. HopeMed HMI-115 versus Absci ABS-201 dispute (Community discussion · Accessed 2026-09-30)

No tested combination in these accounts: Other hair-treatment names are comparisons, and community hypotheses do not establish additive benefits. [community]

Watch for

Long exposure	Posters worry that an unwanted reaction could be harder to end than stopping a daily product; this is a concern, not a documented reaction.
Trial adverse events	The sponsor's blinded interim report includes mostly mild events such as headache. Active and placebo participants were pooled.
Pregnancy and breastfeeding	The study excludes both. Community discussion does not establish safety for fertility, lactation or medicine combinations.
Systemic effects	Targeting scalp hair does not establish scalp-only exposure or make prolactin-lowering drugs interchangeable with this antibody.

Notes

A long-lasting injection raises reversibility concerns. Planetariano worries an unwanted reaction could be harder to end than stopping a daily product. That is a reversibility concern, not a documented reaction. Long-term effects remain unsettled. Australian hair-loss trial: eligibility, travel and participant concerns (Community discussion · Accessed 2026-09-30) · Rapamycin forum ABS-201 discussion (Community guide · Accessed 2026-09-30)

Early safety reporting includes adverse events. The sponsor's blinded 32-person interim summary reports no serious events, but does include mostly mild events such as headache. Active and placebo participants are pooled, preventing an ABS-201-specific event-rate conclusion. Absci June 24 interim HEADLINE Phase 1 release (Official context · Accessed 2026-09-30)

Pregnancy and breastfeeding remain outside reassurance. The registered study excludes pregnancy and breastfeeding and requires participants to avoid pregnancy. Community debate about prolactin, fertility and lactation does not establish safety in those settings or with other medications. NCT07317544 current protocol registration (Official context · Accessed 2026-09-30)

Prolactin-first enthusiasm meets direct pushback. Bioenergetic Forum's haidut frames the pathway as overturning DHT and suggests dopamine-agonist substitutes. alfredoolivas challenges that leap. The tressless debate likewise separates receptor targeting from reducing circulating prolactin; these drugs cannot be assumed interchangeable. Prolactin antagonist cure claim and contrary reply (Community opinion · Accessed 2026-09-30) · Prolactin the Cause of Hair Loss? ABS-201 the Cure? (Community opinion · Accessed 2026-09-30)

A scalp target does not mean scalp-only action. User453 asks about selective hair effects and compares the stem-cell story with GHK-Cu. These questions establish neither combination benefit nor scalp-only exposure. Rapamycin discussion explicitly raises systemic blockade. MPB: has anyone seen this video on ABS-201? (Community opinion · Accessed 2026-09-30) · Rapamycin forum ABS-201 discussion (Community guide · Accessed 2026-09-30)

Source context — Rapamycin forum ABS-201 discussion: Mechanistic synthesis, not self-use. At least one reply explicitly generated with Claude; not treated as independent literature verification. OP's authorship method unknown. Trial numbers share sponsor origin. Only discussion priorities used.

Source context — Prolactin antagonist cure claim and contrary reply: Page says topic deleted but extracted body and reply visible. OP republishes haidut.me and quotes Popular Mechanics; same origin family, not independent accounts. Cure, shedding and dopamine-substitution claims not accepted. Commercial associations possible; no outcome log. Exact date unavailable.

Source context — MPB: has anyone seen this video on ABS-201?: Lay hypothesis/questions, not findings. Assumption of scalp-only action is not supported. GHK-Cu analogy is speculative; no combo outcomes reported.

Full notes

ABS-201 is an investigational antibody people follow for pattern hair loss. The attraction is fuller regrowth with infrequent injections, possibly lasting after treatment stops. Discussion mixes trial news, hope and skepticism; the inspected accounts do not yet establish a personal regrowth timeline or a consumer regimen.

What ABS-201 is

An antibody aimed at the prolactin receptor. ABS-201 is a large engineered protein designed to block the receptor that receives prolactin signals. This is a different approach from finasteride, minoxidil or PP405. Blocking that receptor is also different from lowering a blood prolactin result. Official context Reddit / tressless
Injection research, with two distinct routes. The registered study separates single IV doses, delivered into a vein, from repeated SC doses, injected beneath the skin. These are different delivery methods and study arms. A claimed gray-market vial or peptide-style recipe cannot verify the named trial product. Official context Community

What people hope it will change

Thicker coverage, not just less shedding. Hair-loss posters hope miniaturized hairs will become visibly thicker again. smurfsays considers the target promising but doubts it will fully reverse baldness. That is a reasoned community prediction, not a result from taking ABS-201. Reddit / tressless
Fewer treatment days and possible pigment changes. Interview replies imagine an alternative to constant medication and discuss gray-hair reversal. The same exchange pushes back on calling it a cure and worries about future cost. Regrowth, pigmentation and sexual-function claims remain expectations, not demonstrated personal benefits. Reddit / HairlossResearch

Doses people discuss

No established community dose or daily total. These discussions provide trial announcements and questions, not a documented self-use amount with route, frequency and outcome. No dependable consumer quantity emerges from these accounts. Trial milligrams are kept separately below; they are not a daily injection chart. Community Reddit / tressless
Higher-dose arguments are still arguments. Ieson posters dispute comparisons between human and monkey exposure. One contributor later identifies a Discord summary as their source. Neither animal-to-human arithmetic nor a claim that HMI-115 was underdosed establishes how much ABS-201 a person should receive. Ieson / Calvizie.net

Half-life

At least 65 days: a sponsor-derived human trial estimate. This number circulates in the Phase 1 news repost. It originates in Absci's interim blood-concentration data after single IV trial doses, not a community measurement. It is a provisional estimate, not a countdown to complete clearance or the length of hair improvement. Reddit / HairlossResearch

When people notice a change

No dependable firsthand regrowth or feel-clock here. Surviving replies to a deleted trial-question post ask whether enrollment happened and how hair growth is going; they do not supply an answer. A prediction about a future hair-count assessment cannot establish when a participant first sees growth, shedding or a bodily change. Reddit / tressless Community

How long a benefit might last

Years of regrowth are animal-comparator lore. One HMI-115 comparison thread turns four-year macaque follow-up into hope for lasting ABS-201 benefit. Those earlier anti-prolactin-receptor animal observations do not measure human ABS-201 durability. No inspected personal account establishes persistence after stopping. Reddit / HairlossResearch Reddit / tressless
Trial follow-up is not benefit duration. A participant-question thread discusses a 480-day commitment. That is reported study time, not 480 days of regrowth from a dose. Posters also fear losing gains afterward; neither the optimistic nor pessimistic prediction settles that question. Reddit / tressless Reddit / tressless

Courses and repeat treatment

Two or three injections over six months is a development target. The announcement repost repeats Absci's proposed interval, derived from trial drug-level data. It is not a community-tested cycle. The discussions do not establish a repeat-course calendar, time off or whether maintenance would be needed. Reddit / HairlossResearch Community

Good to know

A long-lasting injection raises reversibility concerns. Planetariano worries an unwanted reaction could be harder to end than stopping a daily product. That is a reversibility concern, not a documented reaction. Long-term effects remain unsettled. Reddit / tressless Community guide
Pregnancy and breastfeeding remain outside reassurance. The registered study excludes pregnancy and breastfeeding and requires participants to avoid pregnancy. Community debate about prolactin, fertility and lactation does not establish safety in those settings or with other medications. Official context Community

From community discussion

Trial access can conflict with an existing routine. ParticularParsnip435 says dutasteride use prevented registration and reports being told one month off was needed. Other comments describe much longer exclusions and repeated travel. The current registry differs from that one-month story; these are screening accounts, not directions to stop treatment. Reddit / tressless Official context
An apparent adverse reply has important missing context. Affectionate-Let4751 later mentions constipation and a hemorrhoid. Their trial-related comments do not identify dose, confirmed ABS-201 receipt, placebo status or causality. This remains one ambiguous account, not two side-effect reports or an established drug reaction. Reddit / tressless Reddit / tressless
Prolactin-first enthusiasm meets direct pushback. Bioenergetic Forum's haidut frames the pathway as overturning DHT and suggests dopamine-agonist substitutes. alfredoolivas challenges that leap. The tressless debate likewise separates receptor targeting from reducing circulating prolactin; these drugs cannot be assumed interchangeable. Bioenergetic Forum Reddit / tressless
A scalp target does not mean scalp-only action. User453 asks about selective hair effects and compares the stem-cell story with GHK-Cu. These questions establish neither combination benefit nor scalp-only exposure. Rapamycin discussion explicitly raises systemic blockade. Reddit / tressless Community guide
HMI-115 comparisons are disputed, not a stack. Posts argue about potency, receptor coverage and absent hair-loss data; a HopeMed complaint is also reposted. The dispute does not prove either drug's superiority. PP405, GT20029, pyrilutamide, finasteride and minoxidil remain comparison names, not a tested ABS-201 combination. Reddit / HairlossResearch Community

What the trial information actually says

Trial amounts are separate from consumer practice. Absci lists single IV cohorts of 150, 450, 900 and 1,800 mg; repeated SC cohorts use 300, 600 or 1,200 mg per administration, or placebo. These are distinct study arms, not daily totals or interchangeable routes. Official context
Early safety reporting includes adverse events. The sponsor's blinded 32-person interim summary reports no serious events, but does include mostly mild events such as headache. Active and placebo participants are pooled, preventing an ABS-201-specific event-rate conclusion. Official context
The macaque story has an older compound origin. Absci's slide labels the durable-regrowth macaque material as a Bayer-commissioned competitor study. That is supporting anti-PRLR animal history, not human ABS-201 efficacy. It cannot turn a hope for sustained regrowth into a promised result. Animal context